Gracell Biotechnologies, a Suzhou immune cell gene therapy company, announced a new technology, FasT CAR-T, that shortens the manufacturing time of CAR-T treatments from two weeks to one day. FasT CAR-T also lowers manufacturing costs to a fraction of previous CAR-T therapies, said Gracell, while showing higher potency of CD19-directed FasT CAR-T in B-Cell acute lymphoblastic leukemia (B-ALL) (20-40 times) and non-Hodgkin Lymphoma (NHL), both in vitro and in vivo. More details....
Share this with colleagues: